Page 18 - MEMOCiberehd014-ENG

P1. PORTAL HYPERTENSION AND MECHANISMS OF TRANSITION TO CIRRHOSIS
Coordinator:
Dr. A. Albillos
Associate Coordinators: Drs. JC García-Pagán, J Genescà and P. Ginès
Program num . 1 focuses on collaborative research on the pathogenesis, diagnosis and treatment of liver cirrhosis, portal hypertension and complications . In particular, the cooperative translational research the Program maintains studies the pathogenic mechanisms of hepatic fibrogenesis and portal hypertension and seeks to develop drugs and therapeutic strategies to improve portal hypertension and its associated complications (bleeding gastroesophageal varices, ascites and renal failure, bacterial infection, hepatic
encephalopathy) . Research is systematised in five lines 1) hepatic fibrogenesis, 2) portal hypertension, 3) ascites/renal function and liver failure, 4) infection and bacterial translocation, and 5) hepatic encephalopathy .
The Program is formed by eight groups, five located in Barcelona and led by Dr . Ginés (Hospital Clinic), Dr . Bosch (Hospital Clinic), Dr . Genescá (Hospital Valle Hebron), Dr . Guarner (Hospital San Pablo) and Dr . Planas (Hospital Germán Trias Pujol), two in Madrid led by Dr . Albillos (Hospital Ramón y Cajal-Universidad de Alcalá) and Dr . Bañares (Hospital Gregorio Marañón), and one in Alicante led by Dr . Such (Hospital General) . In spite of its clinical origin, all the groups included in the Program have incorporated experimental research . The latter fact enables Program 1 to cover the whole spectrum of translational research in its field of expertise, including studies of cell and molecular biology, proof of concept in patients with cirrhosis and clinical trials to evaluate different drugs and treatment strategies .
The strategic aim of CIBEREHD is to promote clinical and experimental collaborative research . In this sense, CIBEREHD management has stimulated the development of collaborative projects among groups of Program 1, as well as with groups in other areas . The collaboration has included multicentre clinical trials, cooperation to evaluate prognostic markers and test and design strategies for diagnosis and treatment with a direct impact on clinical practice . One of the initial goals of CIBEREHD was to extend this collaboration towards mechanistic basic research, using the advantages of cell and molecular biology . Cooperation in this sense has also been initiated among CIBEREHD groups and is expected to continue growing in coming years .
The following table describes the topics of research for the 8 groups of Program 1:
Group
Centre
PI
Lines of research
CB06/04/0024
Universidad de Alcalá- Hospital Ramón y Cajal, Madrid
Agustín Albillos
Portal hypertension Infection/Translocation
CB06/04/0020
Hospital Clínic Barcelona
Pere Ginés
Fibrogenesis Ascites/renal function/ Liver failure Infection/Translocation Hepatic encephalopathy
CB06/04/0082
Hospital Gregorio Marañón, Madrid
Rafael Bañares
Portal hypertension Ascitis/renal function /Liver failure
CB06/04/0026
Hospital Clínic Barcelona
Jaime Bosch
Portal hypertension Infection/Translocation
18 CIBEREHD » Annual report 2014